Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | CCR3 | P51677 | 2/20 | 0.76 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160829 | 0.94 | OPRL1 (0.79) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| SCHEMBL1411499 | 0.89 | OPRL1 (1.00) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| SCHEMBL27679284 | 0.87 | OPRL1 (0.77) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| SCHEMBL3890625 | 0.86 | OPRL1 (0.82) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| SCHEMBL653218 | 0.86 | CCR3 (1.00) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| SCHEMBL13573604 | 0.85 | OPRL1 (0.66) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| SCHEMBL2591097 | 0.85 | OPRL1 (0.79) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| SCHEMBL6110923 | 0.85 | OPRL1 (0.79) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| SCHEMBL3898508 | 0.85 | OPRL1 (0.79) | OPRL1POLBCCR3DRD4SIGMAR1 | |
| Bromide SCHEMBL28537686 | 0.84 | CCR3 (0.94) | OPRL1POLBCCR3DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847181-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013170115-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20080268071-A1 | SUBSTITUTED CYCLOHEXANONES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268071-A1 | SUBSTITUTED CYCLOHEXANONES | GRIN2B, GRIN3A, GRIN1 | OPRL1 27/4885POLB 3565/4885CCR3 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.